ArticleToxins2026
OnabotulinumToxinA Reduces Pharmacological Burden in Chronic Migraine Patients: A Two-Center Prospective Cohort Study.
Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic migraine (CM) is a highly disabling and difficult-to-manage condition with a high pharmacological and economic burden. OnabotulinumtoxinA (BTx) was the first treatment specifically approved for CM. The main aim of this study was to assess whether the initiation of BTx is associated with discontinuation of previously prescribed preventive therapies.
methodsThis study was a prospective cohort investigation conducted in two headache centers: Carlo Besta (Milan) and Policlinico Campus Bio-Medico (Rome). We included patients with CM and previous oral preventive treatments initiating BTx. We analyzed persistence with preventive therapies over 12 months of follow-up and evaluated the conversion rate from chronic to episodic migraine (EM), along with change in migraine days, symptomatic intake, and HIT-6.
resultsA total of 95 patients were included in the main analysis, showing a discontinuation of treatment in 28.4% of patients at 12 months. In the exploratory analysis, a CM to EM conversion rate of 58.9% was achieved at 12 months; meanwhile, HIT-6, migraine days, and symptomatic intake showed a sizeable improvement.
conclusionTreatment with BTx was associated with a reduction in drug burden at 12 months and a CM to EM conversion rate of almost 60% at 12 months, also contributing to a reduction in the economic burden of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.